FDA approves new generic valsartan to reduce the shortage of drug
Category: #health  By Pankaj Singh  Date: 2019-03-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

FDA approves new generic valsartan to reduce the shortage of drug

The regulator reviewed the manufacturing and testing practices of India-based Alkem Laboratories Limited and found no traces of impurity

The United States Food and Drug Administration (FDA) has reportedly announced to have approved a new generic version of valsartan to reduce the recent shortage of the medicine. As per trusted sources, the drug is primarily utilized to treat high blood pressure.

Reportedly, the FDA has issued several recalls of the generic version of valsartan drug since last summer from numerous manufacturers after it found nitrosamine impurities which pose a cancer risk to patients. It is being said that the regulator discovered impurities in only the generic version and not the brand name valsartan.

Commissioner of the FDA, Dr. Scott Gottlieb was reportedly quoted saying that the agency is aware of the ongoing recalls to stop specific batches of valsartan containing non-acceptable limits of impurities from reaching patients has led to a shortage of the important medicines. The FDA prioritized review of the newly approved generic version of valsartan to address the shortage, Gottlieb.

He also claimed that the approval would assist in reducing the shortage of valsartan and that the agency would remain committed to implement measures to avert the formation of the impurities during drug production procedures for existing and new products. Reportedly, the FDA would also work with pharmaceutical firms to ensure other similar blood pressure drugs, part of a type of drugs known as angiotension II receptor blockers, or ARBs, are available to customers.

According to the report by USA Today, the FDA reviewed the manufacturing and testing practices of India-based Alkem Laboratories Limited to ascertain whether its valsartan contains impurities found in the recalled blood pressure drugs of its rivals.

Reportedly, Alkem Laboratories is yet to reveal whether it plans to sell the drug in the United States.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

EU, China ink deals to reinforce partnership on civil aviation safety
EU, China ink deals to reinforce partnership on civil aviation safety
By Pankaj Singh

The agreements will enable passengers to benefit from safer, economical, and greener air travel options The European Union (EU) has reportedly signed two agreements on civil aviation with China that are aimed at creating jobs, boost growth and bring...

Cook Medical, Ambu A/S to jointly address endoscope-related infections
Cook Medical, Ambu A/S to jointly address endoscope-related infections
By Pankaj Singh

The two firms will bring forth single-use endoscopes to patients undergoing ERCP procedures to reduce the risk associated with serious cross-contaminations. Medical device company, Cook Medical Incorporated has recently agreed to enter into a partne...

Mastercard Lyft tie up to strengthen economic security of drivers
Mastercard Lyft tie up to strengthen economic security of drivers
By Pankaj Singh

Mastercard, the financial services company announced an expanded partnership with a U.S. based transportation network company, Lyft, to bring tools to Lyft drivers for their growth in the ever-changing scenario of the gig economy. A bank account and...